-
-
-
GEMINI Trial; CAMELOT Trial; INVEST Trial; The Dangers of Vitamin E; FDA Actions.
-
The FDA has approved a 5-nitroimidazole for the treatment of trichomoniasis, giardiasis, and amebiasis. Tinidazole, a second-generation nitroimidazole antiprotozoal agent, is marketed as Tindamax by Presutti Laboratories.
-
The FDA has approved a combination of 2 antiretrovirals, abacavir and lamivudine, for the treatment of HIV-1 infections. Each tablet contains 600 mg of abacavir and 300 mg of lamivudine for once daily administration. The combination is marketed by GlaxoSmithKline as Epzicom.
-
All 165 cases of malaria-related deaths in the United States reported to the National Malaria Surveillance System from 1963 to 2001 were reviewed. Two-thirds occurred in US travelers, and 92.7% of deaths were due to Plasmodium falciparum infection.
-
Dial and colleagues point out that Clostridium difficile is the most common form of nosocomial infectious diarrhea in the Western world, apparently increasing in frequency, severity, and consequential health care costs (more than $1 billion in the United States annually).
-
-
The Infection Risk of Acid-Suppressing Drugs; Is Rosuvastatin As Safe As Other Statins?; Which Estrogen Preparation is the Safest?; FDA Actions.
-
This is an observational cohort study that compared HIV patients who acquired TB or bacterial pneumonia with comparison of those 2 groups of patients without TB or bacterial pneumonia, respectively. Poor prognosis for HIV-infected individuals after TB may be due to preexisting high HIV load, rather than to the TB event itself.
